Predictive factors of lamivudine treatment success in an hepatitis B virus-infected pediatric cohort: a 10-year study (Q36091371)

12 August 2017

Predictive factors of lamivudine treatment success in an hepatitis B virus-infected pediatric cohort: a 10-year study (English)

1 reference

12 August 2017

1 reference

1 reference

Yasmine Yousef

1

1 reference

12 August 2017

Kathie Beland

2

1 reference

12 August 2017

Emmanuel Mas

3

1 reference

12 August 2017

Pascal Lapierre

4

1 reference

12 August 2017

Dorothée Bouron Dal Soglio

5

1 reference

12 August 2017

Fernando Alvarez

6

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 2012

1 reference

Canadian Journal of Gastroenterology

12 August 2017

0 references

volume

26

1 reference

12 August 2017

7

1 reference

12 August 2017

429-435

1 reference

Creative Commons Attribution-NonCommercial 4.0 International

12 August 2017

start time

1 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Management of Hepatitis B: A Longitudinal National Survey – Impact of the Canadian Hepatitis B Consensus Guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Natural history and clinical management of chronic hepatitis B virus infection in children

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

National Institutes of Health consensus development conference statement: management of hepatitis B.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Endpoints of therapy in chronic hepatitis B.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Benefits and risks of nucleoside analog therapy for hepatitis B.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Interferon treatment for chronic hepatitis B: enhanced response in children 5 years old or younger

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus--large-scale analysis using a new genotyping method

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

The treatment of chronic viral hepatitis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

No benefit to continue lamivudine therapy after emergence of YMDD mutations

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Response to Lamivudine Treatment in Children with Chronic Hepatitis B Virus Infection

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Clinical trial of lamivudine in children with chronic hepatitis B.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Microwave treatment of serum facilitates detection of hepatitis B virus DNA by the polymerase chain reaction. Results of a study in anti-HBe positive chronic hepatitis B.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3395443

Long-term outcome in children with chronic hepatitis B: a 24-year observation period

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22803017

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Spontaneous Seroconversion in Hepatitis B e Antigen‐Positive Chronic Hepatitis B: Implications for Interferon Therapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22803017

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Long-term therapeutic efficacy of lamivudine compared with interferon-alpha in children with chronic hepatitis B: the younger the better

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22803017

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1155/2012/928912

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

22803017

1 reference